Matsukiyococokara & Co. · TSE:3088
Matsukiyococokara & — FY2025 Earnings Presentation
16 slides from Matsukiyococokara &'s earnings presentation, May 13, 2026
Slide 1: Supplementary Presentation Financial Results for the Fiscal Year Ended March 31, 2026
This document is a translation of the original Japanese document for reference purposes only. In the event of any discrepancy between this document and the Japanese original, the original shall prevail. Supplementary Presentation Financial Results for the Fiscal Year Ended March 31, 2026 Copyright 2
Slide 2: Table of Contents
Table of Contents Financial Results for FY2025 Financial Summary YoY (Full Year) ・・・・・・ 2 Segment Results YoY (Full Year) ・・・・・・ 3 Segment Results YoY (Full Year) (Reference) ・・・・・・ 4 Excl. amortization of goodwill and trademarks from business integration and acquisitions Net Sales by Product ・・・・・・
Slide 3: Financial Summary YoY (Full Year)
Financial Results for FY2025 Financial Summary YoY(Full Year) ◼ Sales increased, driven by the consolidation of MATSUMOTO KIYOSHI (HK) CO., LIMITED and Shinseidoyakkyoku co., ltd.as well as strong sales of cosmetics, and net sales achieved the plan. ◼ Operating profit sales were slightly below the p
Slide 4: Segment Results YoY (Full Year)
Financial Results for FY2025 Segment Results YoY(Full Year) ◼ In the Matsumotokiyoshi Group business, sales and profit increased due to strong sales of cosmetics, store openings in urban areas, and promotion of in-store prescription drug stores. ◼ While Cocokarafine Group business saw a decline in b
Slide 5: Segment Results YoY (Full Year) (Reference)
Financial Results for FY2025 Segment Results YoY(Full Year) ◼ Excluding amortization of goodwill and trademark rights of cocokara fine Inc. totaling ¥7.237 billion Reference ◼ Excluding amortization of goodwill and trademark rights of Shinseidoyakkyoku co., ltd. totaling ¥172 million (Millions of ye
Slide 6: Net Sales by Product
Financial Results for FY2025 Net Sales by Product ◼ The composition ratio of the health and beauty category increased to 72.4%, driven by cosmetics, mainly in new merchandise. ◼ Gross profit margin improved due to steady promotion of priority measures and strengthening of sales of PB products, exclu
Slide 7: Balance Sheet
Financial Results for FY2025 Balance Sheet ◼ Total assets increased by approximately ¥43.0 billion from the end of the previous fiscal year. Net assets increased by approximately ¥22.9 billion due to an increase in Retained earnings. ◼ Liabilities increased by approximately ¥20.1 billion due to an i
Slide 8: Statement of Cash Flows
Financial Results for FY2025 Statement of Cash Flows ◼ We have continued to actively and systematically implement shareholder returns, with share buybacks of approximately ¥15.3 billion, dividend payments of approximately ¥18.9 billion, and a decrease in financing cash flow of approximately ¥34.1 bi
Slide 9: Store Openings, Closings, and Renovations in Japan
Financial Results for FY2025 Store Openings, Closings, and Renovations in Japan ◼ Strategic store openings in major metropolitan areas, including the Matsumotokiyoshi Ikebukuro Higashiguchi Gosaro-mae store and Higashi-ginza store. ◼ Reopening of SHIBUYA SCRAMBLE FLAG as our sixth flagship store. (U
Slide 10: Assumptions for FY2026 Financial Forecasts
Financial Forecasts for FY2026 Assumptions for FY2026 Financial Forecasts １．Assumptions Same-Store Sales Growth Full Year +0.7％（1H +0.7％、2H +0.6％） Openings 130（MKG 100、CFG 30） Closings 60（MKG 20、CFG 40） Renovations 80（MKG 50、CFG 30） AppBrew Inc. , UNIVERSAL DRUG CO.,LTD. Newly consolidated （Shinseid
Slide 11: FY2026 Financial Forecasts (Quarterly)
Financial Forecasts for FY2026 FY2026 Financial Forecasts（Quarterly） Full Year 1H 2H 1Q 2Q 3Q 4Q YoY YoY YoY YoY YoY YoY YoY （Millions of yen/%） (%/pt) (%/pt) (%/pt) (%/pt) (%/pt) (%/pt) (%/pt) Net sales 1,155,000 103.4 572,000 104.2 284,000 103.8 288,000 104.6 583,000 102.6 299,000 103.0 284,000 10
Slide 12: Shareholder Return Policy
Financial Forecasts for FY2026 Shareholder Return ◼ We have set a target dividend on equity (DOE) ratio of 6% and a dividend payout ratio of 50% for the fiscal year ending March 31, 2031. ◼ Maintain or increase dividends Progressive dividend policy. ◼ We will flexibly implement share buyback, taking
Slide 13: Quarterly Consolidated Financial Results
【Appendix】 Quarterly Consolidated Financial Results FY2024 FY2025 1Q 2Q 1H 3Q 4Q Full Year 1Q 2Q 1H 3Q 4Q Full Year （Millions of yen/%） Net sales 259,749 265,979 525,729 275,791 260,105 1,061,626 273,643 275,451 549,094 290,246 278,099 1,117,440 Gross profit 89,241 93,115 182,357 96,201 93,676 372,2
Slide 14: Quarterly Segment Results
【Appendix】 Quarterly Segment Results FY2024 FY2025 （Millions of yen/％） 1Q 2Q 1H 3Q 4Q Full Year 1Q 2Q 1H 3Q 4Q Full Year Matsumoto- Sales 162,010 166,075 328,085 173,795 165,346 667,226 175,393 176,430 351,823 182,941 176,648 711,413 kiyoshi Segment Group 12,560 13,647 26,208 16,242 15,501 57,952 14
Slide 15: Quarterly Net Sales and Gross Profit by Product
【Appendix】 Quarterly Net Sales and Gross Profit by Product FY2024 FY2025 (Millions of yen/％) 1Q 2Q 1H 3Q 4Q Full Year 1Q 2Q 1H 3Q 4Q Full Year Sales 88,378 90,809 179,187 96,478 93,085 368,752 91,887 93,125 185,012 102,182 100,511 387,707 Medical and Segment pharmaceutical products profit 37,069 40,
Slide 16: Cautionary Statement
Cautionary Statement This document contains future outlooks such as plans, forecasts, strategies, and others which are not historical fact and these are made by the management’s judgement based on the obtainable information at the time of the disclosure. Actual results may significantly differ from